PeppiLibrary

Metabolic

Tirzepatide peptide reference

Dual GIP/GLP-1 receptor agonist. Stronger weight-loss data than semaglutide.

Last reviewed May 6, 2026 FDA-approved FDA approved
Peppi reviewing Tirzepatide notes
Default dose label2.5 mg
Preferred routeSubQ
Frequency label1× weekly
Storage window28 days mixed

Evidence snapshot

FDA-approved

Evidence maturityFDA approved
FDA-approved with Phase 3 trials (SURPASS, SURMOUNT programs)

Prescription medication

Route map

How records are usually labeled

1 SubQ

Rotate weekly between abdomen, thigh and upper arm to minimise lipohypertrophy.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C; do not freeze.
After mixPen in use: room temperature ≤30 °C up to 21 days OR refrigerated 56 days. Compounded vials: refrigerate, use within 28 days.
Use-by cue28 days after mixing
Mixed vial window28 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 10 mg vial
Dose 2.5 mg
Route SubQ
Review 28d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for Tirzepatide. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

Tirzepatide is a synthetic 39-amino-acid peptide developed by Eli Lilly that simultaneously activates both GIP and GLP-1 receptors. The dual-incretin mechanism produces larger reductions in HbA1c and body weight than GLP-1 monoagonists in head-to-head trials. FDA-approved as Mounjaro (T2D, 2022) and Zepbound (chronic weight management, 2023).

Also known as: Mounjaro, Zepbound, LY3298176.

Type 2 diabetes glycemic controlChronic weight management (BMI ≥30 or ≥27 with comorbidity)Metabolic syndrome support

Mechanism and timing snapshot

Dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Slows gastric emptying, increases insulin secretion, suppresses glucagon, and reduces appetite via central pathways.

Onset labelNot listed
Catalog onset field, when available.
Half-life label120 hr
~5 days; weekly dosing reaches steady state in ~4 weeks
Duration label168 hr
Catalog duration field, when available.
subQ ~80%
oral Negligible

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose2.5 mg
Catalog dose range2.5 mg - 15 mg
Default routeSubQ
Frequency label1× weekly
Best time labelSame day each week, any time of day; with or without food.
Food noteNone for the injectable form.

Catalog protocol note

2.5 mg weekly × 4 weeks → 5 mg × 4 weeks → escalate by 2.5 mg every 4 weeks up to 15 mg max.

Routes and site notes

Available route labelsSubQ
Preferred route labelSubQ
Common site labelsAbdomen, Thigh, Upper arm
Site rotation noteRotate weekly between abdomen, thigh and upper arm to minimise lipohypertrophy.

Chemistry

SequenceModified GIP backbone with C20 fatty diacid; 39 amino acids
Amino acids39
Molecular formulaC225H348N48O68
Molecular weight4813.5 Da

Vial, reconstitution, and storage

Supply formPre-filled multi-dose pen (commercial) OR lyophilized powder (compounded)
Typical vial size10 mg
DiluentBacteriostatic water (compounded only)
Diluent volume2 mL
Concentration noteCompounded 10 mg in 2 mL → 0.05 mL = 2.5 mg starting dose. Commercial pens are pre-dosed.
Before reconstitutionRefrigerate 2–8 °C; do not freeze.
After reconstitutionPen in use: room temperature ≤30 °C up to 21 days OR refrigerated 56 days. Compounded vials: refrigerate, use within 28 days.
Reconstituted shelf life28 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Nausea (~25–35%)
  • Diarrhea or constipation
  • Decreased appetite
  • Fatigue
  • Injection-site reactions
  • Pancreatitis
  • Gallbladder issues
  • Acute kidney injury from dehydration
  • Hypoglycemia (when combined with insulin/sulfonylureas)

Contraindications and warnings

  • Personal/family history of medullary thyroid carcinoma
  • MEN 2 syndrome
  • Pregnancy
  • Pancreatitis history (caution)
  • FDA boxed warning for thyroid C-cell tumours (rodent data).
  • Discontinue if pancreatitis suspected.

Other considerations

  • Dual mechanism produces stronger appetite suppression than GLP-1 alone — pace yourself.
  • GI side effects are dose-dependent — escalating slowly is essential.
  • Use a backup contraceptive method during titration if on oral contraceptives.

Evidence and regulatory context

Evidence levelFDA-approved with Phase 3 trials (SURPASS, SURMOUNT programs)
FDA approvedYes
Regulatory statusPrescription medication
Prescription requiredYes
Approved countriesUS, EU, UK, Japan, and many others

Stacking and cycle notes

Stacks well withNot listed
Avoid combining noteOther GLP-1 or GIP agonists, DPP-4 inhibitors (redundant mechanism)
Typical cycle labelongoing
Typical break labelNot typically cycled
Cycle guidanceUsed continuously; weight regain often follows discontinuation. Discuss tapering vs maintenance with a clinician.

Tracking tips

  • Pick a consistent day of the week — set a recurring reminder.
  • Hydrate aggressively and prioritise fibre to manage GI side effects.
  • Use a backup contraceptive during the first 4 weeks if on oral birth control.
  • Discuss with a clinician — this is a regulated medication, not a research peptide.

References

Track it in Peppi

Keep Tirzepatide records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for Tirzepatide?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use Tirzepatide?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export Tirzepatide records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026